I fell behind on this list and I apologize for jumping Into this conversation so late.

The CDC recently came out with 10 milestones in public health that have helped increase human lifespan by 25 years.

http://www.cdc.gov/about/history/tengpha.htm

Enjoy!

Helena

Helena M. VonVille, MLS, MPH
Library Director
University of Texas School of Public Health
Houston, TX
[log in to unmask]<mailto:[log in to unmask]>
713-500-9131
713-500-9125 (fax)
________________________________________
From: Evidence based health (EBH) [[log in to unmask]] On Behalf Of Amy Price [[log in to unmask]]
Sent: Thursday, March 15, 2012 10:51 PM
To: [log in to unmask]
Subject: Re: Wonderful "innovations" in an era of commercialized health care - what is the evidence?

Ash,

I think getting value for money in pharmaceuticals with VBP is the way to go. They are not going to just offer discounts out of goodwill. You know that by the time the 3 billion actually gets to the patients it will be paid for via the interest and the tax breaks . They will charge what the market will bear and unless we refuse to carry an unreasonable load it will only get worse…

Amy

From: Ash Paul <[log in to unmask]<mailto:[log in to unmask]>>
Reply-To: Ash Paul <[log in to unmask]<mailto:[log in to unmask]>>
Date: Wed, 14 Mar 2012 14:57:10 -0700
To: <[log in to unmask]<mailto:[log in to unmask]>>
Subject: Re: Wonderful "innovations" in an era of commercialized health care - what is the evidence?

Dear Roy,
Germany has saved 1.9 billion euros in 2011 using value based pricing (VBP) of drugs and refusing to pay all these outrageous prices that big pharma was asking for all its new marginally effective drugs.
England is also supposed to introduce VBP in 2014. Neal Maskrey and Andy Hutchison from our Group will know a lot more about this, but big pharma is already getting wobbly at the prospect of VBP and is trying to undermine it desperately, is my guess because it recently rolled out its big gun Sir Andrew Witty, CEO of Glaxo (his salary for last year has just been announced - 6.7 million pounds and the GSK Board was saying that he was actually underpaid for the work he was doing; I thought it was rather ironic, considering GSK has now put aside 3 billion dollars to compensate the US victims of the Rosiglitazone debacle) on TV and radio to take a heavy pot shot at NICE and accuse it of delaying the introduction of all these new 'miracle' drugs in England; apparently it was costing big pharma 300 million pounds annually because of this delay.
It was also announced last week that big pharma had paid a total of 8 billion dollars in fraud fines to the US Federal Government in the past 10 years.
Regards,
Ash

________________________________
From: "Poses, Roy" <[log in to unmask]<mailto:[log in to unmask]>>
To: [log in to unmask]<mailto:[log in to unmask]>
Sent: Wednesday, 14 March 2012, 16:25
Subject: Fwd: Wonderful "innovations" in an era of commercialized health care - what is the evidence?

Forwarded on behalf of James McCormack after rejection by list server...

---------- Forwarded message ----------
From: McCormack, James <[log in to unmask]<mailto:[log in to unmask]>>
Date: Wed, Mar 14, 2012 at 12:01 PM

Hi Roy – not sure if this helps but

 1.  I worked for a number of years over the last decade with the Patented Medicines Prices review board in Canada – from 2000-2010, 19 drugs were considered to be a substantial advantage over what we already had, or had an impact for conditions which previously had no treatment – see list below – as you can see most were for relatively "rare" conditions
 2.  In 2011, for the first time ever Prescrire could not identify even one drug that was either a major therapeutic advantage, clear advantage, or modest improvement
 3.  FDA data etc  – between 20 and 25 drugs were "removed" from the market from 2000-2010
 4.  Xigris – one of the substantial advantage drugs was just removed from the market
 5.  Mike Allan, an evidence-based family doctor and I talked about the issue of new not being better and other similar things at a conference in New Zealand a few months ago – the video can be found at http://vimeo.com/31518313

A) PATENTED MEDICINE PRICES REVIEW BOARD – DRUGS CONSIDERED TO BE A SUBSTANTIAL ADVANTAGE OR WERE FOR CONDITIONS WHICH PREVIOUSLY HAD NO TREATMENT

2000
Enbrel – tumour necrosis factor for rheumatoid arthritis
Rilutex – ALS – amyotrophic lateral sclerosis
Visudyne - age-related macular degeneration

2001
Cerezyme - Gaucher disease -glucocerebrosidase deficiency
Prevnar - pneumococcal vaccine for children

2002
Gleevec – chronic myeloid leukemia

2003
Xigris - for severe sepsis

2004
None

2005
Sensipar - hypercalcemia in paients with parathyroid carcinoma

2006
Myozyme - Pompe disease - alfa glucosidase deficiency
RotaTeq - vaccine prevents severe rotavirus gastroenteritis in children
Fuzeon – HIV treatment
Macugen – wet age-related macular degeneration

2007
Aldurazyme - enzyme replacement therapy in patients with Mucopolysaccharidosis I
Replagal - enzyme replacement therapy in patients with alfa-galactosidase A deficiency
Spirafil - anti-fungal

2008
Revlimid - treatment for multiple myeloma
Lucentis - age-related macular degeneration
Relistor - constipation secondary to narcotic drugs

2009
Sprycel - chronic myeloid leukemia


B) DRUGS REMOVED FROM THE MARKET 2000-2010 – FDA etc

Troglitazone (Rezulin)
Hepatotoxicity

Alosetron (Lotronex)
Fatal complications of constipation
Reintroduced 2002 on a restricted basis

Cisapride (Propulsid)
Cardiac arrhythmias

Amineptine (Survector)
Hepatotoxicity
Dermatological side effects
Abuse potential

Phenylpropanolamine (Dexatrim)
Stroke

Trovafloxacin (Trovan)
Liver failure

Cerivastatin (Baycol)
Rhabdomyolysis

Rapacuronium (Raplon)
Fatal bronchospasm

Rofecoxib (Vioxx)
Myocardial infarction

Co-proxamol (Distalgesic)
Overdose dangers

Hydromorphone ER (Palladone)
Overdose dangers

Thioridazine (Melleril)
UK - cardiotoxicity

Pemoline (Cylert)
Hepatotoxicity

Ximelagatran (Exanta)
Hepatotoxicity

Pergolide (Permax)
US - heart valve damage

Tegaserod (Zelnorm)
Heart attack and stroke

Aprotinin (Trasylol)
Death

Inhaled insulin (Exubera)
UK - due to poor sales/doubts
Long-term safety and too high a cost

Lumiracoxib (Prexige)
Liver damage

Rimonabant (Accomplia)
Severe depression and suicide

Efalizumab (Raptiva)
Progressive multifocal leukoencephalopathy

Sibutramine (Reductil)
Cardiovascular risk

Gemtuzumab (Mylotarg)
US – no benefit and venoocclusive disease

Rosiglitazone (Avandia)
Europe - heart attacks and death

James McCormack, BSc (Pharm) Pharm D
Professor
Faculty of Pharmaceutical Sciences, UBC, Vancouver, Canada
medicationmythbusters.com<http://medicationmythbusters.com>